Published in Antimicrob Agents Chemother on July 01, 1998
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg (2010) 1.77
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep (2014) 1.36
A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A (2003) 1.34
Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs. Interdiscip Perspect Infect Dis (2009) 1.32
Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr Top Med Chem (2011) 1.27
Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv Parasitol (2011) 1.24
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist (2012) 1.15
In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother (2004) 1.13
Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother (2004) 1.12
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging. Antimicrob Agents Chemother (2015) 1.09
Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology (2013) 1.07
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother (2007) 1.05
Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob Agents Chemother (2003) 1.02
Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother (2004) 1.01
Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother (2007) 0.99
In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (2000) 0.96
Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Antimicrob Agents Chemother (2015) 0.95
Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother (2011) 0.95
In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS One (2013) 0.95
Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother (2005) 0.94
Squalene synthase as a target for Chagas disease therapeutics. PLoS Pathog (2014) 0.93
In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother (2012) 0.90
Changing Epidemiology and Approaches to Therapy for Chagas Disease. Curr Infect Dis Rep (2003) 0.89
Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition. FEBS Lett (2014) 0.89
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem (2014) 0.88
Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation. Bioorg Med Chem Lett (2007) 0.86
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob Agents Chemother (2008) 0.86
Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo. PLoS One (2011) 0.86
Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death. PLoS One (2013) 0.86
Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line. PLoS Negl Trop Dis (2015) 0.84
Translational challenges of animal models in Chagas disease drug development: a review. Drug Des Devel Ther (2015) 0.83
SQ109, a new drug lead for Chagas disease. Antimicrob Agents Chemother (2015) 0.82
Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis. Antimicrob Agents Chemother (2015) 0.80
Genome profiling of sterol synthesis shows convergent evolution in parasites and guides chemotherapeutic attack. J Lipid Res (2014) 0.78
Assessing anti-T. cruzi candidates in vitro for sterile cidality. Int J Parasitol Drugs Drug Resist (2016) 0.75
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother (1996) 3.20
In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother (1996) 3.08
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg (1987) 2.66
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother (1997) 2.63
Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples from chronic chagasic patients in a rural endemic area. Am J Trop Med Hyg (1994) 1.94
Cure of short- and long-term experimental Chagas' disease using D0870. Science (1996) 1.75
Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology (1997) 1.64
Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology (1995) 1.60
Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol (1995) 1.44
Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother (1993) 1.43
A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz (1993) 1.41
Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1990) 1.39
Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1988) 1.33
Activity of ICI 195,739--a novel, orally active bistriazole--in rodent models of fungal and protozoal infections. Ann N Y Acad Sci (1988) 1.31
Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J Infect Dis (1984) 1.27
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy (1997) 1.17
Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother (1993) 1.16
Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob Agents Chemother (1993) 1.13
Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1991) 1.08
In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg (1986) 1.08
The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop (1993) 1.07
Ultrastructural alterations induced by ICI 195,739, a bis-triazole derivative with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1991) 1.06
Trypanosoma (Schizotrypanum) cruzi: terminal oxidases in exponential and stationary growth phase emipastigotes cultured in vitro. Acta Cient Venez (1984) 1.06
An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz (1993) 1.05
In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J Antimicrob Chemother (1998) 1.00
Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg (1987) 0.98
Suggested guidelines for work with live Trypanosoma cruzi. Trans R Soc Trop Med Hyg (1983) 0.96
Failure of ketoconazole to cure chronic murine Chagas' disease. J Infect Dis (1988) 0.95
[Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi]. Rev Inst Med Trop Sao Paulo (1993) 0.95
Altered lipid composition and enzyme activities of plasma membranes from Trypanosoma (Schizotrypanum) cruzi epimastigotes grown in the presence of sterol biosynthesis inhibitors. Biochem Pharmacol (1997) 0.89
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence. Nat Genet (2000) 14.51
Nonfilamentous C. albicans mutants are avirulent. Cell (1997) 13.83
The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res (2001) 8.63
Genome sequence and gene compaction of the eukaryote parasite Encephalitozoon cuniculi. Nature (2001) 7.53
Genome sequence of the plant pathogen Ralstonia solanacearum. Nature (2002) 6.23
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
Genomic exploration of the hemiascomycetous yeasts: 1. A set of yeast species for molecular evolution studies. FEBS Lett (2000) 3.71
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother (2006) 3.25
Renal injury in the extremely obese patients with normal renal function. Kidney Int (2008) 2.83
Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture. Ophthal Plast Reconstr Surg (2001) 2.82
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother (2000) 2.33
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. Nature (2000) 2.17
Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. J Rheumatol (1995) 2.08
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother (1999) 2.06
DNA from soil mirrors plant taxonomic and growth form diversity. Mol Ecol (2012) 2.03
[Identification of gaps in the clinical patient care of asthma in Spain. Results of the OPTIMA-GEMA survey]. An Sist Sanit Navar (2016) 2.02
Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg (1996) 1.99
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother (2000) 1.98
Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet (1992) 1.87
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Cure of short- and long-term experimental Chagas' disease using D0870. Science (1996) 1.75
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect Immun (2001) 1.75
Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract (2008) 1.74
Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res (1992) 1.70
Genomic exploration of the hemiascomycetous yeasts: 18. Comparative analysis of chromosome maps and synteny with Saccharomyces cerevisiae. FEBS Lett (2000) 1.69
Enteroaggregative Escherichia coli heat-stable enterotoxin is not restricted to enteroaggregative E. coli. J Infect Dis (1996) 1.69
Use of linkage disequilibrium approaches to map genes for bipolar disorder in the Costa Rican population. Am J Med Genet (1996) 1.65
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (2000) 1.64
Transcriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci U S A (2001) 1.64
Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology (1995) 1.60
SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother (1998) 1.55
Assessing the feasibility of linkage disequilibrium methods for mapping complex traits: an initial screen for bipolar disorder loci on chromosome 18. Am J Hum Genet (1999) 1.54
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
In vivo regulation of rat muscle glycogen synthetase activity. Biochemistry (1969) 1.50
Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther (2004) 1.49
Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi epimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol (1995) 1.44
Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother (1993) 1.43
[Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease]. Arch Bronconeumol (2006) 1.43
A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz (1993) 1.41
Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J Biol Chem (1999) 1.39
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene (2007) 1.36
Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1988) 1.33
Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1984) 1.31
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Antibiotic G418, a new micrommomospora-produced aminglycoside with activity apainst protozoa and helminths: antiparasitic activity. Antimicrob Agents Chemother (1975) 1.29
Pure interferon gamma enhances class II HLA antigens on human monocyte cell lines. Eur J Immunol (1984) 1.28
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother (1998) 1.27
Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.25
Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr (1984) 1.25
Conserved linkage groups associated with large-scale chromosomal rearrangements between Old World and New World Leishmania genomes. Gene (1998) 1.21
Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of north-eastern Brazil. Trans R Soc Trop Med Hyg (1996) 1.20
The interaction of a Trypanosoma cruzi surface protein with Vero cells and its relationship with parasite adhesion. Mol Biochem Parasitol (1987) 1.19
Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants. Antimicrob Agents Chemother (2000) 1.19
Genomic exploration of the hemiascomycetous yeasts: 20. Evolution of gene redundancy compared to Saccharomyces cerevisiae. FEBS Lett (2000) 1.18
Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus. Infect Immun (2001) 1.17
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy (1997) 1.17
EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance. Mol Microbiol (2001) 1.17
Detection of microsporidia in surface water: a one-year follow-up study. FEMS Immunol Med Microbiol (2000) 1.17
Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum (1979) 1.16
Genomic exploration of the hemiascomycetous yeasts: 19. Ascomycetes-specific genes. FEBS Lett (2000) 1.16
Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother (1993) 1.16
Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection. Neuroscience (2008) 1.14
SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother (2000) 1.13
Inhibitors of delta24(25) sterol methyltransferase block sterol synthesis and cell proliferation in Pneumocystis carinii. Antimicrob Agents Chemother (1997) 1.13
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer (2008) 1.12
Cerebral auditory plasticity and cochlear implants. Int J Pediatr Otorhinolaryngol (1999) 1.11
Regulation of muscle glycogen synthetase by metabolites. Differential effects on the I and D forms. Biochemistry (1968) 1.11
Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes. Antimicrob Agents Chemother (1996) 1.09
Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother (1991) 1.08
Prenatal diagnosis of solid placental masses: the value of color flow imaging. Ultrasound Obstet Gynecol (2000) 1.08
Chromosome size and number polymorphisms in Leishmania infantum suggest amplification/deletion and possible genetic exchange. Mol Biochem Parasitol (1989) 1.08
Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother (1999) 1.07
[Parameters in the experimental chemotherapy of schistosomiasis 9s. mansoni)]. Acta Cient Venez (1969) 1.07
Cloning and sequencing of a 24-kDa Trypanosoma cruzi specific antigen released in association with membrane vesicles and defined by a monoclonal antibody. Biol Cell (1992) 1.05
Different behavior of two Trypanosoma cruzi major clones: transmission and circulation in young Bolivian patients. Exp Parasitol (1998) 1.04
Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasitol (1999) 1.04
Search for large extra dimensions via single photon plus missing energy final states at sqrt s = 1.96 TeV. Phys Rev Lett (2008) 1.04
Genomic exploration of the hemiascomycetous yeasts: 16. Candida tropicalis. FEBS Lett (2000) 1.04
Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol (1992) 1.03
Systemic lupus erythematosus in males. A study of 107 Latin American patients. Medicine (Baltimore) (1996) 1.02
Procainamide-induced serologic changes in asymptomatic patients. Arthritis Rheum (1969) 1.02
A polymorphic minisatellite sequence in the subtelomeric regions of chromosomes I and V in Leishmania infantum. Mol Biochem Parasitol (1995) 1.02
Plasmid Transfer between Spatially Separated Donor and Recipient Bacteria in Earthworm-Containing Soil Microcosms. Appl Environ Microbiol (1997) 1.01
Sugarcane yellow leaf virus: an emerging virus that has evolved by recombination between luteoviral and poleroviral ancestors. Virology (2000) 1.01
[Recommendations for the care of the patient with chronic obstructive pulmonary disease]. Arch Bronconeumol (2001) 1.01
Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans. Lupus (1997) 1.01
Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies. Gene Ther (2006) 1.00
Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother (2001) 1.00